Clinical trial
Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With…
NCT00160212 · Solvay Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00160212 |
|---|---|
| Title | Study to Evaluate the Efficacy and Safety of SLV306 in Subjects With Hypertension |
| Official title | A Randomized, Placebo-Controlled, Double-Blind, Six-Arm, Dose Escalation, Multi-Center Study to Evaluate the Efficacy and Safety of SLV306: 150, 300, 600 mg Once Daily, 150-300 mg Twice Daily and Amlodipine 5-10 mg Once Daily in Subjects With Hypertension |
| Lead sponsor | Solvay Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | Daglutril |
| Start date | Dec 1, 2004 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 30, 2009 |
| Countries | Australia, Bulgaria, Denmark, Estonia, Germany, Hungary, Israel, Latvia, Lithuania, Slovakia, United Kingdom |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: